CLCM
VRTX icon

Crawford Lake Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Crawford Lake Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,200
Closed -$2.59M – 146
2017
Q1 		$2.59M Buy
+22,200
New +$1.95M 1.03% 33

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Crawford Lake Capital Management's VRTX Position: Q3 2018 in Review

Crawford Lake Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 57,974 shares — an estimated $9.85M sold.

Crawford Lake Capital Management first reported a position in VRTX in Q1 2017 and held it in 5 quarters. The position peaked at $17.6M in Q3 2017. 697 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

  • Crawford Lake Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Crawford Lake Capital Management sold 57,974 Vertex Pharmaceuticals shares in Q3 2018, an estimated $9.85M.
  • Crawford Lake Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Crawford Lake Capital Management's Vertex Pharmaceuticals position peaked at $17.6M in Q3 2017.
  • 697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Crawford Lake Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.